Biosimilar development and commercialization is a uniquely difficult endeavor requiring precise, stepwise planning to ensure timely regulatory approval and optimal market access.

Nigel Rulewski
Nigel Rulewski discusses the first approval of a biosimilar in the United States.

Quintiles Blog

Fresh ideas and insights from our experts around the globe


Quintiles Authors

Vice President Strategic Drug Development, Head, Biosimilar Center of Excellence

Vice President, Global Strategic Drug Development and Head of Global Biosimilars Strategic Planning

Peer-Reviewed Publications